Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... test showcasing data at the ESMO Congress for our Liquid biopsy colon cancer screening test and also ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...

It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening. Exact Sciences's Economic Impact: An Analysis Market ...